Impact of Daily Oral Cannabis Doses in Patients With Cancer

Example Inclusion Criteria: * Histologically or cytologically confirmed locally advanced or metastatic solid tumors with any types. This applies to either newly diagnosed cancer or preexisting ones on treatment. * Patients with active cancers and currently under any line of treatment (please see notable exceptions in the exclusion criteria - patients taking checkpoint inhibitors and investigational agents will not be eligible - also exclusionary medications). * Patients have been taking their current anti-cancer therapy regimen for at least one month prior to enrollment (to ensure no safety or toxicity issues with study drug initiation). * Age ≥18 years. * ECG and lab values demonstrating adequate organ and marrow function at baseline (pre-study). * Negative urine drug screen for all illicit drugs and THC, CBD prior to randomization * Ability to understand and the willingness to sign a written informed consent document * Individuals able to become pregnant will agree to practice an effective form of contraception (e.g., oral birth control pills, condoms, abstinence) for the duration of enrollment (note: urine pregnancy testing will occur monthly) Exclusion Criteria: * History of hypersensitivity to cannabis or cannabinoids * Current, regular use of cannabis/marijuana or THC-containing medications (dronabinol, nabilone) or cannabidiol (Epidiolex) or over-the-counter (OTC) CBD oil. * Concomitant use of checkpoint inhibitors (e.g., anti-PD1, PDL1, CTLA4) or other drugs for which an cannabinoid interaction may occur. * Current use of investigational agents, \<3 months after the use of investigational agents * Cardiac conditions contraindicated for cannabis use * Diagnosis of HPV-related cancer, as there is some evidence that cannabis is contraindicated * Allergy to any constituent/ingredient contained in the edible dose * Psychiatric illness/social situations that would limit compliance with study requirements (e.g., bipolar disorder, psychosis, severe depression/anxiety). * Pregnant or breastfeeding (note: participants will be tested for pregnancy (urine sample) once per month during enrollment) * Current moderate/severe drug or alcohol use disorder (including cannabis use disorder), positive urine drug screen for illicit drugs or cannabis, or positive alcohol (breathalyzer) during screening * History of seizure disorder, epilepsy (controlled or uncontrolled) * Current legal obligations (parole, probation, incarceration, urine drug screen requirements as part of parole/probation/previous incarceration) * Currently enrolled in substance use treatment * Self-reported cannabis and synthetic cannabinoid use in the past 30 days (medical or non-medical use is exclusionary) * Self-reported illicit drug use in past 60 days (ex: methamphetamine, heroin, illicit fentanyl) * Self-reported daily alcohol use * Providing a urine sample testing positive for cannabinoids (THC, CBD) or synthetic cannabinoids (K2, Spice-like compounds) * Providing a sample testing positive for alcohol (breathalyzer) or non-medical use of other drugs (methamphetamine, cocaine) during screening; testing positive during enrollment will lead to discontinuation of the participant's enrollment * No access to internet/data or devices needed to participate in daily video calls